1.
Dhone PG, Behera D, Gupta V, Mubeen MF. To evaluate the safety and efficacy of saroglitazar among pre-diabetes and dyslipidemia. Int. J. of Health Sci. [Internet]. 2022 Jun. 12 [cited 2026 Apr. 29];6(S2):13816-23. Available from: http://www.sciencescholar.us/journal/index.php/ijhs/article/view/8835